1-8 of 8
Matthew Schwede
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Investigational Cell Therapy Beyond Oncology: Education, Communication, and Lessons Learned from Utilizing a Centralized Oncology Based Cell Therapy Program

Neil Bailey, Tenzin Tsomo, Jordan Briggs, Tori Braun, Krystle Pagarigan, Morgan Hanson, Phuong Nam Doan, Kory Barrow, Wezi Longwe, Rachael Crickman, Evonne Lackey, Swathi Namburi, Matthew Schwede, Krish Patel
Journal: Blood
Blood (2024) 144 (Supplement 1): 7956.
https://doi.org/10.1182/blood-2024-208076
Published: 2024
Journal Articles

Circulating Tumor DNA (ctDNA) Enables Superior and Universal Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) Highly Predictive of Relapse Free and Overall Survival

Ruwan Gunaratne, Crystal Zhou, Jesse W. Tai, Sky Kim, Kailee Tanaka, Sanjeeth Rajaram, Mia Carleton, Raymond Yin, Matthew Alkaitis, Matthew Schwede, Brian J. Sworder, Michael S. Khodadoust, Ravi Majeti, David Kurtz, Tian Y Zhang
Journal: Blood
Blood (2024) 144 (Supplement 1): 2955.
https://doi.org/10.1182/blood-2024-201701
Published: 2024
Journal Articles

Acute Myeloid Leukemia with Inv(3) or t(3;3): A Clinical and Cytogenetic Characterization of 40 Patients

Maria Moscvin, Matthew Schwede, Gabriel Mannis, Tian Y. Zhang
Journal: Blood
Blood (2023) 142 (Supplement 1): 4231.
https://doi.org/10.1182/blood-2023-186672
Published: 2023
Journal Articles

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

Ruwan Gunaratne, Crystal Zhou, Jesse W. Tai, Matthew Schwede, Kailee Tanaka, Matthew Alkaitis, Raymond Yin, Brian J. Sworder, Gabriel Mannis, Ravindra Majeti, Michael S. Khodadoust, David M. Kurtz, Tian Y. Zhang
Journal: Blood
Blood (2023) 142 (Supplement 1): 4307.
https://doi.org/10.1182/blood-2023-181459
Published: 2023
Journal Articles

The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-World Study Using Large-Scale Electronic Health Record Data

Matthew Schwede, Gladys Rodriguez, Solomon Henry, Douglas Wood, Gabriel Mannis, Ravindra Majeti, Jonathan Chen, Eran Bendavid, Tian Y. Zhang
Journal: Blood
Blood (2023) 142 (Supplement 1): 958.
https://doi.org/10.1182/blood-2023-187725
Published: 2023
Journal Articles

Harnessing Artificial Intelligence for Risk Stratification in Acute Myeloid Leukemia (AML): Evaluating the Utility of Longitudinal Electronic Health Record (EHR) Data Via Graph Neural Networks

Riya Sinha, Matthew Schwede, Ben Viggiano, David Kuo, Solomon Henry, Douglas Wood, Gabriel Mannis, Ravindra Majeti, Jonathan Chen, Tian Y. Zhang
Journal: Blood
Blood (2023) 142 (Supplement 1): 960.
https://doi.org/10.1182/blood-2023-190151
Published: 2023
Journal Articles

Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the Post-Venetoclax Era

Emma C St. Martin, Matthew Schwede, Bita Fakhri, Jason Gotlib, Michaela Liedtke, William Shomali, Tian Y. Zhang, Gabriel Mannis
Journal: Blood
Blood (2023) 142 (Supplement 1): 1490.
https://doi.org/10.1182/blood-2023-190614
Published: 2023
Journal Articles

Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)

Irena Tan, Matthew Schwede, Paul Phan, Raymond Yin, Tian Y Zhang, Gabriel N. Mannis
Journal: Blood
Blood (2021) 138 (Supplement 1): 1216.
https://doi.org/10.1182/blood-2021-147886
Published: 2021